COMMUNIQUÉS West-GlobeNewswire

-
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
03/06/2024 -
TECVAYLI®▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
03/06/2024 -
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
03/06/2024 -
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
03/06/2024 -
Molecular Templates, Inc. Provides Interim Update
03/06/2024 -
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
03/06/2024 -
InnovAge PACE Recertified as a Great Place to Work
03/06/2024 -
Noom Launches Noom Vibe, a Wellness Community and Habit Tracker Built for the Age of GLP-1s
03/06/2024 -
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
03/06/2024 -
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
03/06/2024 -
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
03/06/2024 -
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
03/06/2024 -
BriaCell Presents Clinical Efficacy Data at ASCO 2024
03/06/2024 -
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
03/06/2024 -
EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
03/06/2024 -
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03/06/2024 -
PetMed Express, Inc. Announces Strategic Updates to Executive Leadership Team
03/06/2024 -
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
03/06/2024 -
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
03/06/2024
Pages